If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Percentage calculated based on 7,833,080 shares of common stock, par value $0.10 per share, outstanding as of August 2, 2024, as reported in the Form 10-Q for the fiscal quarter ended June 30, 2024 of ImmuCell Corporation.


SCHEDULE 13D




Comment for Type of Reporting Person:
Percentage calculated based on 7,833,080 shares of common stock, par value $0.10 per share, outstanding as of August 2, 2024, as reported in the Form 10-Q for the fiscal quarter ended June 30, 2024 of ImmuCell Corporation.


SCHEDULE 13D




Comment for Type of Reporting Person:
Percentage calculated based on 7,833,080 shares of common stock, par value $0.10 per share, outstanding as of August 2, 2024, as reported in the Form 10-Q for the fiscal quarter ended June 30, 2024 of ImmuCell Corporation.


SCHEDULE 13D


 
SRK FUND I, LP
 
Signature:SRK Capital, LLC
Name/Title:general partner
Date:09/17/2024
 
Signature:Sean Kirkwood
Name/Title:Authorized Signatory
Date:09/17/2024
 
SRK Capital, LLC
 
Signature:Sean Kirkwood
Name/Title:manager
Date:09/17/2024
 
Sean Kirkwood
 
Signature:Sean Kirkwood
Name/Title:Sean Kirkwood
Date:09/17/2024